MedTrace Logo

SLV308 for Treatment of Patients With Early Parkinson's Disease

NCT00269516 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 468

Last updated 2008-08-29

No results posted yet for this study

Summary

This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.

Conditions

  • Early Stage Parkinson's Disease

Interventions

DRUG

pardoprunox

fixed dose 6 mg

DRUG

Pardoprunox

fixed dose 12 mg

DRUG

Pardoprunox

12-42mg

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Solvay Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Global Clinical Director Solvay · Solvay Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United States
  • Argentina
  • Belgium
  • Bulgaria
  • Canada
  • Chile
  • Colombia
  • Croatia
  • Finland
  • India
  • Israel
  • Mexico
  • New Zealand
  • Peru
  • Romania
  • Russia
  • Serbia
  • Slovakia
  • South Africa
  • Sweden
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00269516 on ClinicalTrials.gov